No Data
No Data
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Insider Sale: Chief Financial Officer of $AXSM Sells 3,000 Shares
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $195
Mizuho Adjusts Price Target on Axsome Therapeutics to $195 From $137, Keeps Outperform Rating
Earnings Preview: AXSM to Report Financial Results Pre-market on February 18
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $133 to $176